NCT00384111 - Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Follicular LymphomaLymphoma, Follicular

Interventions

DRUG

Zevalin Therapeutic Regimen

Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin

DRUG

R-CVP

Standard R-CVP

Trial Locations (6)

Wellstar-Northwest Georgia Oncology Centers, Marietta

Integrated Community Oncology Network, Jacksonville

Gulfcoast Oncology Associates, St. Petersburg

Tennessee Oncology, Nashville

Chattanooga Oncology Hematology Care, Chattanooga

Oncology Hematology Care Inc., Cincinnati